| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Section on Behavioral Pharmacology (C.V., N.L.O.), Biological Psychiatry Branch and Laboratory of Cellular and Molecular Regulation (S.J.L.), National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892-4090
Address all correspondence and requests for reprints to: Nancy L. Ostrowski, Ph.D., Eli Lilly and Co., Lilly Corporate Center, Building 22, Drop Code 2244, Indianapolis, Indiana 46285.
The comparative distributions of the vasopressin V1b receptor (V1bR) and the oxytocin receptor (OTR) messenger RNAs (mRNAs) are described in male rat brain using in situ hybridization histochemistry. V1bR transcripts were present in forebrain and hypothalamus and were less abundant in mid- and hindbrain regions, similar to the gradient observed with OTR transcripts. Microscopic analyses indicated that V1bR expressing cells typically demonstrated the morphology of neurons and confirmed V1bR gene expression in regions including the olfactory bulb, supraoptic, suprachiasmatic, and dorsomedial hypothalamic nuclei, piriform and entorhinal cortices, hippocampus, substantia nigra, and dorsal motor nucleus of the vagus. Most regions that expressed V1bR mRNA also expressed OTR mRNA, although OTR gene expression was much more extensive than that of the V1bR. V1bR and OTR mRNA distributions were distinct from each other and from that of the V1a receptor mRNA in brain. A few brain regions express only V1bR transcripts such as the dorsomedial hypothalamic nucleus and the external plexiform layer of the olfactory bulb. Other brain regions, such as the fields of Ammon’s horn, the suprachiasmatic nucleus, the substantia nigra pars compacta, and the piriform cortex express mRNAs that encode all three receptor subtypes (V1a, V1b, and OTR), whereas brain areas including the red nucleus and supraoptic nucleus express V1bR and OTR transcripts only. These data suggest functional specialization of the V1b, OTR and V1a receptors in brain.
This article has been cited by other articles:
 |
|
 |
|
  A. Pena, B. Murat, M. Trueba, M. A. Ventura, G. Bertrand, L. L. Cheng, S. Stoev, H. H. Szeto, N. Wo, G. Brossard, et al. Pharmacological and Physiological Characterization of d[Leu4, Lys8]Vasopressin, the First V1b-Selective Agonist for Rat Vasopressin/Oxytocin Receptors Endocrinology, September 1, 2007; 148(9): 4136 - 4146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S.-L. Gal, D. Raufaste, S. Derick, J. Blankenstein, J. Allen, B. Pouzet, M. Pascal, J. Wagnon, and M. A. Ventura Biological characterization of rodent and human vasopressin V1b receptors using SSR-149415, a nonpeptide V1b receptor ligand Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2007; 293(2): R938 - R949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Blevins, M. W. Schwartz, and D. G. Baskin Evidence that paraventricular nucleus oxytocin neurons link hypothalamic leptin action to caudal brain stem nuclei controlling meal size Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2004; 287(1): R87 - R96. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Oshikawa, A. Tanoue, T.-a. Koshimizu, Y. Kitagawa, and G. Tsujimoto Vasopressin Stimulates Insulin Release from Islet Cells through V1b Receptors: a Combined Pharmacological/Knockout Approach Mol. Pharmacol., March 1, 2004; 65(3): 623 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Griebel, J. Simiand, C. Serradeil-Le Gal, J. Wagnon, M. Pascal, B. Scatton, J.-P. Maffrand, and P. Soubrie Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders PNAS, April 30, 2002; 99(9): 6370 - 6375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S.-L. Gal, J. Wagnon, J. Simiand, G. Griebel, C. Lacour, G. Guillon, C. Barberis, G. Brossard, P. Soubrie, D. Nisato, et al. Characterization of (2S,4R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a Selective and Orally Active Vasopressin V1b Receptor Antagonist J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 1122 - 1130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-S. Cui, R. C. Bowen, G.-B. Gu, D. K. Hannesson, P. H. Yu, and X. Zhang Prevention of Cannabinoid Withdrawal Syndrome by Lithium: Involvement of Oxytocinergic Neuronal Activation J. Neurosci., December 15, 2001; 21(24): 9867 - 9876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. H. Burbach, S. M. Luckman, D. Murphy, and H. Gainer Gene Regulation in the Magnocellular Hypothalamo-Neurohypophysial System Physiol Rev, July 1, 2001; 81(3): 1197 - 1267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. F. Palm, E. M. van der Beek, H. J. M. Swarts, J. v. d. Vliet, V. M. Wiegant, R. M. Buijs, and A. Kalsbeek Control of the Estradiol-Induced Prolactin Surge by the Suprachiasmatic Nucleus Endocrinology, June 1, 2001; 142(6): 2296 - 2302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Hernando, O. Schoots, S. J. Lolait, and J. P. H. Burbach Immunohistochemical Localization of the Vasopressin V1b Receptor in the Rat Brain and Pituitary Gland: Anatomical Support for Its Involvement in the Central Effects of Vasopressin Endocrinology, April 1, 2001; 142(4): 1659 - 1668. [Abstract] [Full Text]
|
|
|
|
|
|
G. Griebel, J. Simiand, C. Serradeil-Le Gal, J. Wagnon, M. Pascal, B. Scatton, J.-P. Maffrand, and P. Soubrie Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders PNAS, April 30, 2002; 99(9): 6370 - 6375. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
